Pacira BioSciences, Inc.

NasdaqGS PCRX

Pacira BioSciences, Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2024: USD 694.96 M

Pacira BioSciences, Inc. Revenue is USD 694.96 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 4.40% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.
  • Pacira BioSciences, Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 665.69 M, a 1.78% change year over year.
  • Pacira BioSciences, Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 654.06 M, a 28.02% change year over year.
  • Pacira BioSciences, Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 510.89 M, a 21.32% change year over year.
  • Pacira BioSciences, Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 421.10 M, a 6.95% change year over year.
Key data
Date Revenue Gross Profit Operating Income EBIT
Market news
Loading...
NasdaqGS: PCRX

Pacira BioSciences, Inc.

CEO Mr. Frank D. Lee
IPO Date Feb. 3, 2011
Location United States
Headquarters 5401 West Kennedy Boulevard
Employees 711
Sector Health Care
Industries
Description

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

Similar companies

ITCI

Intra-Cellular Therapies, Inc.

USD 126.89

-0.24%

ALKS

Alkermes plc

USD 28.50

0.53%

PBH

Prestige Consumer Healthcare Inc.

USD 75.78

1.54%

ANIP

ANI Pharmaceuticals, Inc.

USD 54.16

0.43%

PAHC

Phibro Animal Health Corporation

USD 20.28

0.05%

IXHL

Incannex Healthcare Limited

USD 1.77

-1.67%

COLL

Collegium Pharmaceutical, Inc.

USD 33.18

-1.80%

StockViz Staff

January 15, 2025

Any question? Send us an email